tradingkey.logo
tradingkey.logo
Search

Bolt Biotherapeutics Inc

BOLT
Add to Watchlist
6.080USD
+0.170+2.88%
Close 11-13 16:00(ET)
15.75MMarket Cap
LossP/E TTM

Bolt Biotherapeutics Inc (BOLT) Stock Price Target & Forecast

Analyst Rating

Based on 4 analysts giving stock ratings to Bolt Biotherapeutics Inc in the past month.

Buy
0 Strong Buy
2 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
75.000USD+1038.09%

BOLT Analyst Recommendation Trends

In the current month, BOLT has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BOLT average Analyst price target in the last month is 75.000.

2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
0
0
0
Buy
2
2
2
2
2
2
2
2
Hold
2
2
2
2
2
2
2
3
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
4
4
4
4
4
4
4
5

BOLT Analyst Rating for Peer Comparison

Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22

Financial Forecasting

Based on analysts' estimates, BOLT EPS is projected to reach -3.850 in FY2026Q4, following reported EPS of -2.249 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.

EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.85
-3.39
-3.69
-3.85
Actual
-4.31
-4.57
-2.25
--
Surprise
-51.25%
-34.84%
+38.96%
--

FAQs

What is Bolt Biotherapeutics Inc's price target?

Analysts forecast that Bolt Biotherapeutics Inc's price target is USD 75.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 75.00.

How have Bolt Biotherapeutics IncBOLT's recent earnings per share performed?

The market expectation was USD -2.25, while Bolt Biotherapeutics IncBOLT's earnings per share (EPS) for the previous quarter was USD -4.57. EPS for the next quarter is expected at USD -3.85.

What is the analyst rating for Bolt Biotherapeutics Inc?

Based on the ratings of Bolt Biotherapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.